Competition to Austedo and Xenazine is also looming from Neurocrine Biosciences, whose VMAT2 drug Ingrezza (valbenazine) is already approved to treat tardive dyskinesia with a phase 3 readout in ...
After hours: March 12 at 6:24:06 PM EDT Loading Chart for NBIX ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback